Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

3
Immediate Income: Why Individual Stocks Matter

2018-07-12 seekingalpha
Multiple types of securities can be used to find high yields but none are safe as individual stocks.
MLPA UNIT CTL CIF OXLCO OXLCN OXLC PSF KNOP UBS AMZA UBS.PRDCL ULSGF

0
Traveling Down Oxford Lane To The Bank

2018-07-10 seekingalpha
Oxford Lane Capital Corp. (OXLC) is a closed end management investment company, which invests in collateralized loan obligations or CLOs. OXLC offers a solid risk-adjusted return for immediate income investors – which should not be overlooked.
OXLCO OXLCN OXLC

48
Monthly Paid Dividends From 89 All Cap U.S. Equities And 80 Funds For July

2018-07-02 seekingalpha
The July forecast for U.S. Exchange monthly-paid dividends, upsides, and net-gains: 1. Stocks by yield >1% (89); 2. Stocks by price-upside (30); 3. Closed-End Investment Companies, Exchange-Traded Funds & Notes.
SCA CLA HCFT GOOD GECC HRZN HTF ORC OXLCO PFLT OXLCN SCM GOODM GOODN THO CJR.B HTFA AGNC CPTA GOODO GOODP TAHO HCAPL OAKS PSEC OXLC ARR CJREF SCQ HCAP SUNS OAKS.PRA GNL ARR.PRB ARR.PRA GNL.PRA PBB

48
Monthly Paid Dividends From 89 All Cap U.S. Equities & 80 Funds For July

2018-07-02 seekingalpha
The July forecast for U.S. Exchange monthly-paid dividends, upsides, and net-gains: 1. Stocks by yield >1% (89); 2. Stocks by price-upside (30); 3. Closed-End Investment Companies, Exchange-Traded Funds & Notes.
SCA CLA HCFT GOOD GECC HRZN HTF ORC OXLCO PFLT OXLCN SCM GOODM GOODN THO CJR.B HTFA AGNC CPTA GOODO GOODP TAHO HCAPL OAKS PSEC OXLC ARR CJREF SCQ HCAP SUNS OAKS.PRA GNL ARR.PRB ARR.PRA GNL.PRA PBB

22
151 Monthly Paying Dividend SML Equities And 69 Funds For June

2018-06-21 seekingalpha
Here's your June 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains reports. Nano-Cap MoPays are not listed.
SCA CCAOF "NHF" CJ CBL WSR CRLFF AD ALARF CRIUF ORC MHIVF OXLCO OXLCN SCM ATGFF SOT.UN CJR.B ECC AMZA ECCZ AGNC AHOTF ECCY PHK SRRTF QYLD PSEC OXLC ECCB NCV CJREF SCQ ECCA SUNS GNL NCZ NHF GNL.PRA PBB SRT.UN

358
Jane's May Dividend Income Tracker - Retirement Accounts

2018-06-19 seekingalpha
This is the third month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $891.57.
GIS O.PRF WBA ENB OPRF JCI HSY ABBV MMM POL MO SMG IRET.PR DUKH GD IRET.PRC TRV IRET.PRB GPT.PRB MAIN BX CMI ENB RY BNS JNJ TROW GPT VZ ABBV MSFT WPC ADM PFE CLX PM PFBC SKT SCL CTL IRET OXLCM OXLCO TD ETN OXLCN BNS CM MSCA GPT.PRA INTC TD IBM IRET.PRCL RY TNTTF LYB O MSB DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL BMRC DLR CBL

29
In Like A Lamb And Out Like A Lion? The Brown Bag Portfolio May Update

2018-06-04 seekingalpha
I purchased my first individual stock on July 5, 2016, two shares of Ruger (NYSE:RGR). I didn’t know what I was doing. I’d made the decision that I wanted to invest in the market and I guessed that gun sales would increase going into the election and I wanted to catch that trend. At the time I knew nothing about the market, I hadn’t gotten a feel for its daily ups and downs, macro and micro trends, the effects of interest rates, nor did I recognize how quickly the small (at that time TD Ameritrade charged $9.
PEGI D EPR.PRG MAIN EPD OXLCO KEY FUN GSK OXLCN OXLC RGR SIX MSCA.CL T EPR MSCA PEG GSK

49
Monthly Paid Dividends From 85 All Cap U.S. Equities And 80 Funds For June

2018-06-01 seekingalpha
June U.S. Exchange monthly-paid dividends, upsides, and net-gains: 1. Stocks by yield >1% (86); 2. Stocks by price-upside (30); 3. Closed-End Investment Companies, Exchange-Traded Funds & Notes (CEICs/ETFs/ETNs) by yield(80).
SCA CLA HCFT GOOD GECC HRZN HTF ORC OXLCO ROYT OXLCN SCM GOODM GOODN THO CJR.B HTFA AGNC CPTA GOODO GOODP TAHO HCAPL OAKS OXLC ARR CJREF SCQ HCAP SUNS OAKS.PRA GNL ARR.PRB ARR.PRA GNL.PRA

0
Dividend Cuts - Managing Their Impact On Our 'Income Factory'

2018-05-21 seekingalpha
Dividend cuts are an inescapable risk in any investment strategy, especially our Income Factory strategy that depends on re-investing and compounding a steady stream of cash.
ECCB ECCA ECC AMZA ECCZ ECCY OXLCO OXLCN OXLC FOF

18
155 Monthly Pay SML Equities Show 1.85% To 17.92% Yields And 70 Funds Yield 7.16% To 19.5%

2018-05-21 seekingalpha
Here's your April 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Reports. Nano-Cap MoPays are not listed.
SCA CCAOF CBL GOOD AD ALARF ORC OXLCO OXLCN SCM GOODM RNW GOODN CJR.B ECC ECCZ AGNC AHOTF DR.DB.A ECCY GOODO GOODP TRSWF DR MFCSF PSEC OXLC ECCB SCQ CJREF ECCA GNL GNL.PRA PBB

0
Oxford Lane Capital 2018 Q1 - Results - Earnings Call Slides

2018-05-18 seekingalpha
The following slide deck was published by Oxford Lane Capital in conjunction with their 2018 Q1 earnings call.
OXLCO OXLCN OXLC

0
Oxford Lane Capital's (OXLC) CEO Jonathan Cohen on Q4 2018 Results - Earnings Call Transcript

2018-05-17 seekingalpha
Good morning and welcome to the Oxford Lane Capital Fourth Fiscal Quarter Earnings Release Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Jonathan Cohen. Please go ahead.
OXLCO OXLCN OXLC

96
April Showers: The Brown Bag Portfolio April Review

2018-05-03 seekingalpha
I started writing about the Brown Bag Portfolio in August of 2017. At that time, I had an extremely small portfolio of just over $10,000 and was invested in four equities. Some readers questioned why I was writing about my portfolio at all, suggesting that I should just take all the money and throw it into an index fund or let a professional manage it. What insights could I possibly have? Why write about something so small?
PEGI ARCC D EPR.PRG MAIN EPD OXLCO GSK FUN OXLCN OXLC ARU MSCA.CL T EPR MSCA ABBV

39
Monthly Dividend Stocks And Funds: 3 U.S. Lists For May

2018-05-03 seekingalpha
May forecasts for U.S. monthly-paid dividends, upsides, and net-gains: 1. Stocks/yield (94); 2. Stocks/price-upside (30); 3. Closed-End Investment Companies, Exchange-Traded Funds & Notes (CEICs/ETFs/ETNs)/yield (80).
SCA CLA GOOD GECC HRZN HTF ORC OXLCO ROYT OXLCN SCM GOODM GOODN THO CJR.B ECC AMBKP HTFA ECCZ AGNC CPTA DR.DB.A ECCY GOODO GOODP TAHO ACAS DR HCAPL NDRO OAKS MFCSF PSEC OXLC ECCB CJREF SCQ ECCA HCAP OAKS.PRA GNL GNL.PRA PBB

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 691543102